Abstract：ObjectiveTo investigate the short-term efficacy of pegaspargase in the treatment of children with acute lymphoblastic leukemia and its effect on the adverse reactions of children.MethodsIn this study, 86 children with ALL who were scheduled to undergo chemotherapy in our hospital from January 2018 to January 2021 were prospectively selected as the research objects, and all the children were randomly divided into the control group and the study group, with 43 cases in each group, The control group received vincristine + daunorubicin + L-asparaginase + prednisone combined chemotherapy (VDLP scheme); The study group received vincristine + daunorubicin + domestic pegaspargase + prednisone combined chemotherapy (VDPAP scheme). Hemoglobin, percentage of immature cells, platelet count, coagulation function, liver and kidney function were compared between the two groups. The clinical remission rate, average length of hospital stay, number of medication and event-free survival rates at 6 months and 1 year of treatment were compared between the two groups. The adverse reactions of the two groups were compared.ResultsAfter 3 months of treatment, the percentage of immature cells in the study group was significantly decreased, and the hemoglobin and PLT in control group were significantly increased. Compared with control group, the values of ALT, BUN, PT, APTT and TT in study group were significantly increased, while ALB and FIB were significantly decreased. The clinical remission rate in study group was higher than in control group. The hospitalization time and medication times of study group were significantly less than those of control group, and there was no significant difference in the event-free survival rate between the two groups at 6 months and 1 year of treatment. The number of gastrointestinal reactions, allergic reactions and in study group was significantly higher than that in control group. There was no significant difference in other indicators between the two groups.ConclusionPeaspargase has obvious advantages in the treatment of children with ALL. It can not only greatly reduce the myelosuppression of children with ALL, promote lymphocyte maturation, but also significantly improve the coagulation function and clinical remission rate of children with ALL, and greatly reduce adverse reactions reaction, However, relatively speaking, pegaspargase has a certain effect on liver function, and it is necessary to further improve the treatment method to reduce the damage rate of liver cells.
刘燕, 戴莉, 黄倩, 蔡力, 肖李岩. 培门冬酶治疗儿童急性淋巴细胞白血病的近期疗效及对患儿不良反应的影响[J]. 金宝搏官方188学报(医学版), 2023, 20(4): 129-133. LIU Yan, DAI Li, HUANG Qian, CAI Li, XIAO-LI Yan. Short-term efficacy of pegaspargase in the treatment of children with acute lymphoblastic leukemia and its effect on adverse reactions in children. HuNan ShiFan DaXue XueBao(YiXueBan), 2023, 20(4): 129-133.
2023,Vol. 20
